Prostate Cancer - Results from #22860

Optimal management of patients receiving cabazitaxel-based chemotherapy - Abstract June 28, 2013

Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer - Abstract June 27, 2013

Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma - Abstract June 27, 2013

Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort - Abstract June 27, 2013

Angiotensin receptor blockers and risk of prostate cancer among United States Veterans - Abstract June 27, 2013

Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: Implementation of standardized management guidelines - Abstract June 27, 2013

DNA ploidy measured on archived pretreatment biopsy material May correlate with prostate-specific antigen recurrence after prostate brachytherapy - Abstract June 27, 2013

Risk of incisional hernia after minimally invasive and open radical prostatectomy - Abstract June 27, 2013

New early detection of prostate cancer guideline toolkit now available June 27, 2013

Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice - Abstract June 27, 2013

Imaging in prostate cancer - Abstract June 26, 2013

Endorectal MRI and MR spectroscopic imaging of prostate cancer: Developing selection criteria for MR-guided focal therapy - Abstract June 26, 2013

Screening for prostate cancer: Why, how? - Abstract June 26, 2013

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: Results from the European Randomized Study of Screening for Prostate Cancer Section Rotterdam - Abstr June 26, 2013

Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer - Abstract June 26, 2013

Magnetic resonance image in the diagnosis and evaluation of extra-prostatic extension and involvement of seminal vesicles of prostate cancer: A systematic review of literature and meta-analysis - Abstract June 26, 2013

Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy - Abstract June 26, 2013

Prediction of rectum and bladder morbidity following radiotherapy of prostate cancer based on motion-inclusive dose distributions - Abstract June 26, 2013

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: A pharmacogenetic assessment of outcome and toxicity - Abstract June 26, 2013

Charles G. Drake, MD, PhD of Johns Hopkins Kimmel Cancer Center takes time to share his understanding on the rationale for implementing immunotherapy in the treatment of prostate cancer June 25, 2013

Page 1144 of 1436